Johnson & Johnson

Diversified pharma

JNJ · NYSE · United States

Share price · JNJ

$272.70+1.59 (+0.59%) 3M

close as of 2026-11-18 · 24h delayed · vol 7.9M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when JNJ's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Oct 2026+3.8%
  2. 13 Oct 2026-5.7%
  3. 5 Oct 2026-1.2%
  4. 22 Jul 2026+2.0%
  5. 15 Jul 2026-2.7%
  6. 23 Jun 2026+3.4%
  7. 13 May 2026+2.7%
  8. 23 Apr 2026+2.0%
  9. 28 Jan 2026+1.5%
  10. 13 Jan 2026+1.9%

Share of unusual movement by asset

For each asset, the share of JNJ's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
guselkumab (Tremfya)
events and moves
288%
Daratumumab
events and moves
327%
Amivantamab
events and moves
245%
icotrokinra (Icotyde)
events and moves
174%
Teclistamab
events and moves
223%
Ciltacabtagene autoleucel
events and moves
152%
Lazertinib
events and moves
122%
Talquetamab
events and moves
81%
Lumateperone (Caplyta)
events and moves
81%
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) (Rybrevant Faspro)
events and moves
6shown from 8 days
Esketamine (Spravato)
events and moves
3shown from 8 days
ustekinumab (Stelara)
events and moves
2shown from 8 days
Cetrelimab
events and moves
2shown from 8 days
Erdafitinib (Balversa) (Balversa)
events and moves
2shown from 8 days
NBTXR3
events and moves
2shown from 8 days
JNJ-78934804
events and moves
1shown from 8 days
JNJ-89495120
events and moves
1shown from 8 days
Ramantamig
events and moves
1shown from 8 days
golimumab (Simponi)
events and moves
1shown from 8 days
bleximenib
events and moves
1shown from 8 days
Tapentadol
events and moves
1shown from 8 days
TAR-210
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—8%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—36%

Assets

(57 total)
57Total Assets
31Approved
11Phase 3 / Filed
15Phase 1–2 / Early
39Diseases
Quick filter:
Showing 57 of 57 assets
Target & Modality
Approved
EGFR x c-METMultispecific antibody
Non-Small Cell Lung CancerColorectal CancerHead and Neck Squamous Cell Carcinoma
Bosentan(Tracleer)
Approved
Endothelin receptor (ETA/ETB, dual)Small molecule
Pulmonary Arterial HypertensionSystemic Sclerosis
Canagliflozin(Invokana)
Approved
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease
Approved
BCMACell therapy
Multiple Myeloma
Approved
CD38Monoclonal antibody
Multiple MyelomaAmyloidosis
AL Amyloidosis
Darunavir(Prezista)
Approved
HIV proteaseSmall molecule
HIV
Approved
FGFR1-4Small molecule
Non-Small Cell Lung CancerBladder / Urothelial Cancer
Urothelial Carcinoma
Esketamine(Spravato)
Approved
NMDA receptorSmall molecule
Major Depressive Disorder
Etravirine(Intelence)
Approved
HIV reverse transcriptaseSmall molecule
HIV
golimumab(Simponi)
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease
guselkumab(Tremfya)
Approved
IL-23 p19Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Approved
Dopamine D2 receptor (antagonist)Small molecule
Schizophrenia
Approved
BTKSmall molecule
Diffuse Large B-Cell LymphomaGraft-versus-Host DiseaseMantle Cell LymphomaChronic Lymphocytic Leukemia
Chronic Graft-versus-Host Disease
icotrokinra(Icotyde)
Approved
IL-23 receptorPeptide
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
infliximab(Remicade)
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(75 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
MilvexianPhase 3Atrial Fibrillation
Est. primary completion 2026-12-08 · NCT05757869 · CT.gov ↗
What to watch
ACI-35.030Phase 2Alzheimer Disease
Est. primary completion 2026-12-22 · NCT06544616 · CT.gov ↗
What to watch
CetrelimabPhase 3Urinary Bladder Neoplasms
Est. primary completion 2026-12-30 · NCT04658862 · CT.gov ↗
What to watch
SeltorexantPhase 3Depressive Disorder, Major
Est. primary completion 2026-12-30 · NCT06559306 · CT.gov ↗
What to watch
IbrutinibPhase 3Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma …
Est. primary completion 2026-12-31 · NCT01804686 · CT.gov ↗
What to watch
2027 (26)
January 2027 (2)
Amivantamab + CetrelimabPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-01-31 · NCT05908734 · CT.gov ↗
What to watch
Macitentan · OpsumitPhase 3Hypertension, Pulmonary
Est. primary completion 2027-01-31 · NCT05179876 · CT.gov ↗
What to watch
February 2027 (3)
guselkumab · TremfyaPhase 3Colitis, Ulcerative
Est. primary completion 2027-02-10 · NCT06260163 · CT.gov ↗
What to watch
icotrokinra · IcotydePhase 3Arthritis, Psoriatic
Est. primary completion 2027-02-10 · NCT06807424 · CT.gov ↗
What to watch
Daratumumab + Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (2)
DeulumateperonePhase 2Generalized Anxiety Disorder
Est. primary completion 2027-03-16 · NCT06480383 · CT.gov ↗
What to watch
guselkumab · TremfyaPhase 3Fistulizing Crohns Disease, Perianal Crohns Disease
Est. primary completion 2027-03-25 · NCT05347095 · CT.gov ↗
What to watch
April 2027 (3)
Lumateperone · CaplytaPhase 3Major Depressive Disorder
Est. primary completion 2027-04-05 · NCT05850689 · CT.gov ↗
What to watch
AmivantamabPhase 1/2Advanced or Metastatic Colorectal Cancer
Est. primary completion 2027-04-27 · NCT05379595 · CT.gov ↗
What to watch
AmivantamabPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-04-28 · NCT05488314 · CT.gov ↗
What to watch
May 2027 (1)
Lazertinib + AmivantamabPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-05-31 · NCT06120140 · CT.gov ↗
What to watch
June 2027 (5)
guselkumab · TremfyaPhase 3Crohn's Disease
Est. primary completion 2027-06-08 · NCT06408935 · CT.gov ↗
What to watch
RamantamigPhase 2Multiple Myeloma
Est. primary completion 2027-06-14 · NCT07266441 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2027-06-21 · NCT06690398 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2027-06-21 · NCT06706674 · CT.gov ↗
What to watch
TalquetamabPhase 2Hematological Malignancies
Est. primary completion 2027-06-30 · NCT04634552 · CT.gov ↗
What to watch
July 2027 (1)
Daratumumab + TalquetamabPhase 3Multiple Myeloma
Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗
What to watch
August 2027 (2)
Lazertinib + AmivantamabPhase 2Carcinoma, Non-small-Cell Lung
Est. primary completion 2027-08-17 · NCT05498428 · CT.gov ↗
What to watch
Talquetamab + Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2027-08-26 · NCT06550895 · CT.gov ↗
What to watch
September 2027 (1)
ustekinumab · StelaraPhase 3Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Est. primary completion 2027-09-29 · NCT05092269 · CT.gov ↗
What to watch
October 2027 (2)
DeulumateperonePhase 2Generalized Anxiety Disorder
Est. primary completion 2027-10-14 · NCT06701903 · CT.gov ↗
What to watch
guselkumab · TremfyaPhase 3Crohn's Disease
Est. primary completion 2027-10-27 · NCT05923073 · CT.gov ↗
What to watch
November 2027 (1)
PasritamigPhase 3Prostatic Neoplasms, Castration-Resistant
Est. primary completion 2027-11-19 · NCT07225946 · CT.gov ↗
What to watch
December 2027 (3)
IbrutinibPhase 2Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Est. primary completion 2027-12-15 · NCT05963074 · CT.gov ↗
What to watch
AmivantamabPhase 3Colorectal Neoplasms
Est. primary completion 2027-12-15 · NCT06750094 · CT.gov ↗
What to watch
DeulumateperonePhase 2Agitation Associated With Alzheimer's Dementia
Est. primary completion 2027-12-28 · NCT06651567 · CT.gov ↗
What to watch
2028 (22)
January 2028 (1)
icotrokinra · IcotydePhase 3Colitis, Ulcerative
Est. primary completion 2028-01-14 · NCT07196748 · CT.gov ↗
What to watch
February 2028 (1)
JNJ-101556143Phase 3Prostatic Neoplasms
Est. primary completion 2028-02-14 · NCT07906717 · CT.gov ↗
What to watch
March 2028 (2)
Lazertinib + AmivantamabPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-03-02 · NCT07586202 · CT.gov ↗
What to watch
Erdafitinib (Balversa)Phase 1/2Non-Muscle Invasive Bladder Neoplasms
Est. primary completion 2028-03-30 · NCT05316155 · CT.gov ↗
What to watch
April 2028 (2)
TAR-210Phase 3Non-Muscle Invasive Bladder Neoplasms
Est. primary completion 2028-04-06 · NCT06919965 · CT.gov ↗
What to watch
Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2028-04-12 · NCT07149857 · CT.gov ↗
What to watch
June 2028 (3)
JNJ-78934804Phase 3Crohn Disease
Est. primary completion 2028-06-12 · NCT07577843 · CT.gov ↗
What to watch
TAR-210Phase 3Non-Muscle Invasive Bladder Neoplasms
Est. primary completion 2028-06-28 · NCT06319820 · CT.gov ↗
What to watch
NBTXR3Phase 3Carcinoma, Squamous Cell
Est. primary completion 2028-06-30 · NCT04892173 · CT.gov ↗
What to watch
August 2028 (4)
JNJ-78934804Phase 3Colitis, Ulcerative
Est. primary completion 2028-08-11 · NCT07577856 · CT.gov ↗
What to watch
JNJ-101556143Phase 1/2Metastatic Prostate Cancer
Est. primary completion 2028-08-17 · NCT06800313 · CT.gov ↗
What to watch
Pasritamig + JNJ-87189401Phase 3Metastatic Castration-resistant Prostatic Neoplasms
Est. primary completion 2028-08-18 · NCT07164443 · CT.gov ↗
What to watch
SeltorexantPhase 3Depressive Disorder, Major
Est. primary completion 2028-08-24 · NCT07573176 · CT.gov ↗
What to watch
September 2028 (2)
icotrokinra · IcotydePhase 2/3Crohn Disease
Est. primary completion 2028-09-19 · NCT07196722 · CT.gov ↗
What to watch
DeulumateperonePhase 2Psychotic Disorders, Alzheimer Disease
Est. primary completion 2028-09-30 · NCT06540833 · CT.gov ↗
What to watch
November 2028 (2)
guselkumab · TremfyaPhase 3Crohn Disease
Est. primary completion 2028-11-15 · NCT07499232 · CT.gov ↗
What to watch
AmivantamabPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-11-30 · NCT07227025 · CT.gov ↗
What to watch
December 2028 (5)
RamantamigPhase 3Multiple Myeloma
Est. primary completion 2028-12-12 · NCT07258511 · CT.gov ↗
What to watch
AmivantamabPhase 3Colorectal Neoplasms
Est. primary completion 2028-12-15 · NCT06662786 · CT.gov ↗
What to watch
Esketamine · SpravatoPhase 3Depressive Disorder, Treatment-Resistant
Est. primary completion 2028-12-27 · NCT07716098 · CT.gov ↗
What to watch
bleximenibPhase 1/2Acute Leukemia
Est. primary completion 2028-12-29 · NCT04811560 · CT.gov ↗
What to watch
NBTXR3Phase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-12-31 · NCT06667908 · CT.gov ↗
What to watch
2029 (10)
January 2029 (1)
DaratumumabPhase 3Multiple Myeloma
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
February 2029 (1)
Ciltacabtagene autoleucelPhase 3Multiple Myeloma
Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗
What to watch
April 2029 (1)
RamantamigPhase 3Multiple Myeloma
Est. primary completion 2029-04-29 · NCT07518186 · CT.gov ↗
What to watch
May 2029 (2)
JNJ-101556143Phase 2Prostatic Neoplasms
Est. primary completion 2029-05-17 · NCT07832292 · CT.gov ↗
What to watch
Lazertinib + AmivantamabPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2029-05-23 · NCT06667076 · CT.gov ↗
What to watch
June 2029 (2)
AmivantamabPhase 3Squamous Cell Carcinoma of Head and Neck
Est. primary completion 2029-06-18 · NCT07276399 · CT.gov ↗
What to watch
bleximenibPhase 3Leukemia, Myeloid, Acute
Est. primary completion 2029-06-22 · NCT06852222 · CT.gov ↗
What to watch
September 2029 (3)
JNJ-95597528Phase 2Asthma
Est. primary completion 2029-09-11 · NCT07746687 · CT.gov ↗
What to watch
CetrelimabPhase 3Bladder Cancer
Est. primary completion 2029-09-18 · NCT05714202 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3Depressive Disorder, Major
Est. primary completion 2029-09-20 · NCT07747389 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
DeulumateperonePhase 3Generalized Anxiety Disorder
Est. primary completion 2030-02-18 · NCT07807865 · CT.gov ↗
What to watch
May 2030 (1)
RamantamigPhase 2Multiple Myeloma
Est. primary completion 2030-05-30 · NCT06500884 · CT.gov ↗
What to watch
September 2030 (3)
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
Daratumumab + RamantamigPhase 3Multiple Myeloma
Est. primary completion 2030-09-04 · NCT07665450 · CT.gov ↗
What to watch
DeulumateperonePhase 3Generalized Anxiety Disorder
Est. primary completion 2030-09-20 · NCT07856420 · CT.gov ↗
What to watch
2031 (4)
April 2031 (2)
Esketamine · SpravatoPhase 3Depressive Disorder, Major
Est. primary completion 2031-04-09 · NCT07227454 · CT.gov ↗
What to watch
Daratumumab + Teclistamab + TalquetamabPhase 3Multiple Myeloma
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch
October 2031 (1)
Lumateperone · CaplytaPhase 3Bipolar Depression
Est. primary completion 2031-10-31 · NCT06372964 · CT.gov ↗
What to watch
December 2031 (1)
guselkumab · TremfyaPhase 3Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Est. primary completion 2031-12-12 · NCT06663332 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
Lumateperone · CaplytaPhase 3Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Est. primary completion 2032-04-28 · NCT06229210 · CT.gov ↗
What to watch
December 2032 (1)
AmivantamabPhase 1/2Squamous Cell Carcinoma of Head and Neck
Est. primary completion 2032-12-27 · NCT06385080 · CT.gov ↗
What to watch
2037 (1)
January 2037 (1)
Daratumumab + RamantamigPhase 3Multiple Myeloma
Est. primary completion 2037-01-11 · NCT07903272 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(52)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2026ApprovalRybrevant Faspro (amivantamab and hyaluronidase-lpuj)FDA grants accelerated approval to Rybrevant Faspro in head and neck cancer
US, FDA · Johnson & Johnson · Source ↗
23 October 2026ApprovalTeclistamabEC approves Tecvayli monotherapy in relapsed/refractory myeloma from first relapse
EU, European Commission · Source ↗
21 September 2026Topline resultLumateperoneStudy 451 phase 3 topline
Johnson & Johnson · Source ↗
14 September 2026Topline resultJNJ-89495120Phase 2 MOONLIGHT-1 (NCT06785012) of JNJ-89495120 (PIPE-307) in major depressive disorder did not meet its primary endpoint
Contineum Therapeutics · Source ↗
September 2026ApprovalicotrokinraEuropean Commission approves ICOTYDE in plaque psoriasis
EU, EC · Johnson & Johnson · Source ↗
28 August 2026ApprovalustekinumabFDA approves Stelara for pediatric ulcerative colitis
US, FDA · Janssen · Source ↗
5 August 2026WithdrawalIloprostFDA withdraws approval of NDA 021779 (Federal Register 2026-13616)
US, FDA · Source ↗
August 2026ApprovalTeclistamabEC approves teclistamab plus daratumumab from second line
EU, EC · Johnson & Johnson · Source ↗
30 July 2026Priority reviewRybrevant Faspro (amivantamab and hyaluronidase-lpuj)FDA grants Priority Review to RYBREVANT FASPRO sBLA in head and neck cancer
US, FDA · Source ↗
23 July 2026Topline resultTalquetamabPhase 3 MonumenTAL-6 (NCT06208150) positive topline: Tec-Tal and Tal-P improved progression-free survival vs EPd/PVd
US · Johnson & Johnson · Source ↗
13 June 2026Filing submittedTalquetamabJ&J has submitted a US sBLA for TALVEY plus DARZALEX FASPRO, with or without pomalidomide (MonumenTAL-3)
US, FDA · Johnson & Johnson · Source ↗
28 May 2026ApprovalguselkumabFDA approves TREMFYA label expansion for inhibition of structural joint damage in PsA
US, FDA · Source ↗

The 12 most recent of 52 past events are shown.

Financial reports

Quarterly & interim (20)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$25.4B$4.7B$16.9B+ $318M short-term inv.—$7.7B operating cash flowreport ↗
View 19 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$25.3B$3.7B$20.4B+ $336M short-term inv.—$8.6B operating cash flowreport ↗
2026-Q1$24.1B$3.5B$22.1B+ $363M short-term inv.—$2.5B operating cash flowreport ↗
2025-Q4$24.6B$4.3B$20.1B—report ↗
2025-Q3$24.0B$3.7B$18.6B+ $331M short-term inv.—$9.2B operating cash flowreport ↗
2025-Q2$23.7B$3.5B$18.9B+ $303M short-term inv.—$3.9B operating cash flowreport ↗
2025-Q1$21.9B$3.2B$38.8B+ $307M short-term inv.—$4.2B operating cash flowreport ↗
2024-Q4$22.5B$5.3B$24.5B—report ↗
2024-Q3$22.5B$5.0B$20.3B+ $317M short-term inv.—$8.0B operating cash flowreport ↗
2024-Q2$22.4B$3.4B$25.5B+ $597M short-term inv.—$5.6B operating cash flowreport ↗
2024-Q1$21.4B$3.5B$25.5B+ $745M short-term inv.—$3.7B operating cash flowreport ↗
2023-Q4$21.4B$3.4B$19.7B+ $3.8B short-term inv.—$7.5B operating cash flowreport ↗
2023-Q3$25.5B$3.8B$21.2B+ $7.3B short-term inv.—$4.2B operating cash flowreport ↗
2023-Q2$24.7B$3.6B$26.9B+ $5.4B short-term inv.$68M$3.3B operating cash flowreport ↗
2023-Q1$19.9B—$14.1B+ $9.4B short-term inv.—$5.3B operating cash flowreport ↗
2022-Q4$23.8B$3.6B$11.4B+ $22.7B short-term inv.—$6.3B operating cash flowreport ↗
2022-Q3$24.0B$3.7B$11.0B+ $21.6B short-term inv.—$5.6B operating cash flowreport ↗
2022-Q2$23.4B$3.5B$10.5B+ $19.9B short-term inv.—$4.0B operating cash flowreport ↗
2021-Q4$23.3B$3.4B$17.6B+ $13.4B short-term inv.—$8.3B operating cash flowreport ↗
2021-Q3$23.3B$3.4B$14.3B+ $11.0B short-term inv.—$5.3B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$94.2B$14.7B$20.1B+ $393M short-term inv.—$24.5B operating cash flowreport ↗

Reported revenue was $94,193M, up 6.0% YoY, with U.S. sales of $53.8B and international sales of $40.4B. R&D spend was $14,665M, down 14.9% YoY; cash, cash equivalents and marketable securities totaled $20.1B at year-end. Net income was $26,804M.

Although no formal financial guidance was provided, management said continued global launches of STELARA biosimilars would keep pressuring sales and expected generic OPSUMIT entry in 2026 could significantly reduce future sales. The company completed the Intra-Cellular Therapies acquisition in April 2025, announced a planned Orthopaedics separation in October 2025 with a targeted completion within 18–24 months, and expected a MedTech Surgery restructuring to be substantially complete by the end of fiscal 2026. Pipeline activity included numerous regulatory approvals and filings across products such as DARZALEX, TREMFYA, SPRAVATO, RYBREVANT, CAPLYTA, ICOTYDE, and IMAAVY, while the company also reversed approximately $7.0B of a previously accrued talc reserve.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$88.8B$17.2B$24.5B+ $417M short-term inv.—$24.3B operating cash flowreport ↗
2023-FY$85.2B$15.1B$22.9B+ $9.4B short-term inv.—$21.2B operating cash flowreport ↗
2022-FY$93.8B$14.7B$14.5B+ $17.1B short-term inv.—$23.4B operating cash flowreport ↗
2021-FY$82.6B$12.2B$14.0B+ $11.2B short-term inv.—$23.5B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($258K), 29 sales ($154.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12Forminard Elizabeth · EVP, Chief Legal OfficerOption exercise13,072$151.41$2.0MForm 4
2026-11-12Forminard Elizabeth · EVP, Chief Legal OfficerOpen-market sale13,072$284.39$3.7MForm 4
2026-11-12Forminard Elizabeth · EVP, Chief Legal OfficerOption exercise (derivative)13,072——Form 4
2026-09-08HEWSON MARILLYN A · directorAward / grant (derivative)180.956$276.31$50KForm 4
2026-09-08Woods Eugene A. · directorAward / grant (derivative)135.717$276.31$37KForm 4
2026-09-08Pinto Daniel E · directorAward / grant (derivative)113.098$276.31$31KForm 4
2026-09-02Schmid Timothy · EVP, WW Chair, MedTechOption exercise11,070$131.94$1.5MForm 4
2026-09-02Schmid Timothy · EVP, WW Chair, MedTechOpen-market sale11,070$274.74$3.0MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 4,578 reporting institutions held 1772.2M shares ($418.0B, 73.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.213,385,546$52.2B
2VANGUARD CAPITAL MANAGEMENT LLC156,605,370$38.3B
3STATE STREET CORP133,476,288$32.6B
4VANGUARD PORTFOLIO MANAGEMENT LLC63,514,436$15.5B
5JPMORGAN CHASE & CO63,096,344$15.3B
6GEODE CAPITAL MANAGEMENT, LLC59,164,862$14.4B
7MORGAN STANLEY44,721,167$10.9B
8STATE FARM MUTUAL AUTOMOBILE INSURANCE CO31,590,952$7.7B
9NORTHERN TRUST CORP29,319,669$7.2B
10BANK OF AMERICA CORP /DE/25,516,697$6.2B
11FMR LLC24,771,828$6.1B
12Bank of New York Mellon Corp21,821,962$5.3B
13WELLINGTON MANAGEMENT GROUP LLP20,075,375$4.9B
14UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC19,628,113$4.8B
15Legal & General Group Plc19,347,862$4.7B